Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Muc1 Is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy Publisher



Hosseinzadeh A1 ; Merikhian P1 ; Naseri N1 ; Eisavand MR1 ; Farahmand L1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, South Gandi, Vanak Squar, Tehran, 1517964311, Iran

Source: Cancer Cell International Published:2022


Abstract

Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC). Some patients show resistance to trastuzumab, and scientists want to circumvent this problem. This review elaborately discusses possible resistance mechanisms to trastuzumab and introduces mucin 1 (MUC1) as a potential target efficient for overcoming such resistance. MUC1 belongs to the mucin family, playing the oncogenic/mitogenic roles in cancer cells and interacting with several other oncogenic receptors and pathways, such as HER2, β-catenin, NF-κB, and estrogen receptor (ERα). Besides, it has been established that MUC1- Cytoplasmic Domain (MUC1-CD) accelerates the development of resistance to trastuzumab and that silencing MUC1-C proto-oncogene is associated with increased sensitivity of HER2+ cells to trastuzumab-induced growth inhibitors. We mention why targeting MUC1 can be useful in overcoming trastuzumab resistance in cancer therapy. © 2022, The Author(s).
Related Docs
View other Related Docs
1. Significant Role of Muc1 in Development of Resistance to Currently Existing Anti-Cancer Therapeutic Agents, Current Cancer Drug Targets (2018)
2. Crosstalk Between Muc1 and Vegf in Angiogenesis and Metastasis: A Review Highlighting Roles of the Muc1 With an Emphasis on Metastatic and Angiogenic Signaling, Cancer Cell International (2021)
3. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
4. Comparison of Mucin-1 in Human Breast Cancer and Canine Mammary Gland Tumor: A Review Study, Cancer Cell International (2022)
5. Muc1 Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer, Expert Review of Anticancer Therapy (2017)
6. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)
7. Anti-Muc1 Nanobody Conjugated by Chitosan Nanoparticle With Enhancement of Anti-Proliferation Activity in Breast Cancer Cell Lines, Chemical Papers (2023)
8. Challenges of Endocrine Therapy in Breast Cancer, Cancer Genetics and Psychotherapy (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Mohammad Mehdi Amiri (3)
Other Related Docs
9. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
10. Breast Cancer Immunotherapy: Current and Novel Approaches, International Immunopharmacology (2021)
11. Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches, Pharmacogenomics and Personalized Medicine (2019)
12. Tumor Immunology, Clinical Immunology (2022)
13. Combination Therapy of Macromolecules and Small Molecules: Approaches, Advantages, and Limitations, Nanostructures for Cancer Therapy (2017)
14. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression, International Immunopharmacology (2023)
15. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
16. Triple-Negative Breast Cancer: Understanding Wnt Signaling in Drug Resistance, Cancer Cell International (2021)
17. Empagliflozin Treatment of Cardiotoxicity: A Comprehensive Review of Clinical, Immunobiological, Neuroimmune, and Therapeutic Implications, Biomedicine and Pharmacotherapy (2023)
18. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
19. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
20. A Review of Salivary Biomarkers in Breast Cancer, Current Women's Health Reviews (2023)
21. Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced Her2-Positive Breast Cancer Patients, International Journal of Hematology-Oncology and Stem Cell Research (2021)
22. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)
23. Dendrosomal Curcumin Suppresses Metastatic Breast Cancer in Mice by Changing M1/M2 Macrophage Balance in the Tumor Microenvironment, Asian Pacific Journal of Cancer Prevention (2015)
24. Epitope Mapping of Human Her2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains, Asian Pacific Journal of Cancer Prevention (2017)
25. Licensed Monoclonal Antibodies and Associated Challenges, Human Antibodies (2015)
26. Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors, Molecular Oncology (2022)
27. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
28. Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review, Vaccines (2023)
29. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May Be Induced by Interactions Between Receptor Tyrosine Kinases and Erα-66, Recent Patents on Anti-Cancer Drug Discovery (2018)